eXoZymes financials
$6.10+1.67%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$3.0M | -$2.4M | -$2.7M | -$2.5M | -$2.5M | -$2.0M |
| Net income | -$2.9M | -$2.4M | -$2.7M | -$2.3M | -$2.4M | -$1.9M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-0.33 | $-0.28 | $-0.32 | $-0.27 | $-0.28 | $-0.22 |
| EBITDA | -$2.9M | -$2.3M | -$2.6M | -$2.5M | -$2.5M | -$1.9M |
| Operating cash flow | -$1.6M | -$1.5M | -$2.0M | -$1.9M | -$1.5M | -$1.1M |
| Free cash flow | -$1.6M | -$1.6M | -$2.0M | -$1.9M | -$1.6M | -$1.2M |
| Diluted shares | 8.7M | 8.5M | 8.4M | 8.4M | 8.4M | 8.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.7M | $1.4M | $3.0M | $5.1M | $7.0M | $8.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $87.0K | $97.9K | $108.7K | $119.2K | $129.6K | $0.00 |
| Total assets | $8.0M | $4.0M | $6.0M | $7.7M | $9.7M | $11.5M |
| Total liabilities | $4.3M | $2.5M | $2.6M | $2.3M | $2.4M | $2.6M |
| Shareholders' equity | $3.7M | $1.5M | $3.4M | $5.4M | $7.2M | $8.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology